Crossmark

NMO spectrum disorders: clinical or molecular classification?

Crossref DOI link: https://doi.org/10.1038/nrneurol.2016.9

Published Online: 2016-02-05

Published Print: 2016-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pittock, Sean J.
License Information

Text and Data Mining valid from 2016-02-05
More Information

Article History

First Online: 5 February 2016

Competing interests

: The author is a named inventor on patents (#12/678,350, filed 2010, and #12/573,942, filed 2008) that relate to functional AQP4/NMO-IgG assays and NMO-IgG as a cancer marker. He receives research support from Alexion Pharmaceuticals, and has provided consultation to Alexion Pharmaceuticals, MedImmune and Chugai Pharma, but has received no personal fees or personal compensation for these consulting activities; all compensation for consulting activities is paid directly to the Mayo Clinic.